Company / Working Capital
Ligand Pharmaceuticals, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$794.8M
FY2025
5-year range
$164.8M / $794.8M
FY2021-FY2025
Trend
+169.9%
vs FY2024
Sector context
#50 of 213
Health Care
What the data says
Ligand Pharmaceuticals, Inc.'s working capital of $795M is higher than 77% of companies in the Health Care sector (FY2025). Working Capital has increased for 3 consecutive years, from $165M in FY2022 to $795M in FY2025.
Based on SEC 10-K filings.
$795M in FY2025 with a 5-year CAGR of +14.7%. Top quartile in the Health Care sector.
Improved from $221M to $795M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +69.0%
- 5-Year CAGR
- +14.7%
- 10-Year CAGR
- -
Sector benchmark
-15.0% below sector average
Key checks
Key Insights
- Ligand Pharmaceuticals, Inc.'s working capital has grown for 3 consecutive years.
- 5-year CAGR of +14.7%, indicating consistent growth.
- In FY2025, working capital increased 169.9% year-over-year.
- Ranks #50 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $794.8M | +169.9% |
| FY2024 | $294.4M | +33.4% |
| FY2023 | $220.6M | +33.9% |
| FY2022 | $164.8M | -61.1% |
| FY2021 | $423.1M | +5.7% |
| FY2020 | $400.4M | -63.8% |
| FY2019 | $1.1B | +40.4% |
| FY2018 | $788.3M | +42779.5% |
| FY2017 | -$1.8M | +97.1% |
| FY2016 | -$64.1M | -690.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026